Evidence map›Paper›PMID 35309351›Full record

ArticleFrontiers in immunology2022

Qiyu Yang, Jing Ouyang, Damao Pi, Li Feng, Jiadan Yang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Soluble Human Lectins at the Host-Microbe Interface.Annual review of biochemistry · 2024
    Review
  16. Review
  17. Identification ofJournal of immunology research · 2022
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Qiyu YangDepartment of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.
Jing OuyangChongqing Public Health Medical Center, Chongqing, China.
Damao PiDepartment of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li FengDepartment of Pharmacy, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, Chongqing, China.
Jiadan YangDepartment of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Cancer Hospital · CNChongqing Medical and Pharmaceutical College · CNChongqing Medical University · CNChongqing Public Health Medical Center · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence indicates that patients with inflammatory bowel disease (IBD) have a significantly higher risk of developing different cancers, while the exact mechanism involved is not yet fully understood.

Indexed as

Inflammatory Bowel DiseasesMalasseziaMycobiomeAnimalsCarcinogenesisCell Transformation, NeoplasticChronic DiseaseDysbiosisHumansMammalsMicecancerfungusinflammationinflammatory bowel diseaseMalassezia

Identifiers

PMID35309351
PMCPMC8931276
OpenAlexW4214947138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.